The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.01
Bid: 2.00
Ask: 2.15
Change: 0.055 (2.72%)
Spread: 0.15 (7.50%)
Open: 2.07
High: 2.07
Low: 1.91
Prev. Close: 2.02
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: Just Eat Leaps As It Gobbles Up Takeaways

Fri, 05th Feb 2016 10:32

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Friday.
----------
FTSE 100 - WINNERS
----------
BG Group, up 1.1%. The oil and gas company reported full-year results that met market expectations as a 16% fall in revenue caused a steep drop in underlying earnings. The company, which is set to merge with Royal Dutch Shell, reported business performance earnings, which excludes special items and measures the underlying performance of the business, of USD1.69 billion in 2015 compared to USD4.03 billion a year earlier after revenue dropped 16%. BG Group didn't manage an overall profit, reporting a pretax loss of USD1.16 billion. However, that is still significantly narrower than the USD8.33 billion pretax loss in 2014. Before special items, BG managed a USD367.0 million profit compared to USD1.15 billion profit in 2014.

Shell 'A' and 'B' share classes both up 1.7%. The oil and gas major was adding to its gains from Thursday, supported by stable oil prices. Brent crude quoted at USD34.70 a barrel, having closed at USD34.62 on Thursday.
----------
FTSE 100 - LOSERS
----------
AstraZeneca, down 0.3%. The pharmaceutical company saw further losses from Thursday, when it guided for a decline in earnings and revenue in 2016.
----------
FTSE 250 - WINNERS
----------
Just Eat, up 7.6%. The online takeaway platform said it has acquired four takeaway businesses for a total of EUR125.0 million, in a move to beef up its position in four different countries. Just Eat said it bought takeaway food businesses from Rocket Internet in Spain and Italy, and from foodpanda in Brazil and Mexico, with the acquisitions to be paid for with existing cash on its balance sheet.

Shaftesbury, up 2.1%. The real estate investment trust said it has continued to see strong tenant demand, underpinned by robust footfall and spending, while making "good progress" with its major schemes. The company which owns retail, restaurant and leisure assets across London's West End, reported EPRA vacancy of 2.0% at the end of December 2015, versus 1.6% at the end of September. Available to let vacancy comprised 13,200 square feet at the same stage, made up of retail space, two restaurants, office space and five apartments.

Victrex, up 2.2%. N+1 Singer upgraded its rating on the stock to Buy from Hold.

Micro Focus International, up 1.5% at 1.360.51p. Wizard Parent LLC, which is owned by Francisco Partners, Golden Gate Capital, Thoma Bravo LLC and Elliott Management Corp, Friday said it upsized the number of shares it was selling in the FTSE 250 software company after its placing was met with strong demand from investors. Wizard raised GBP357.0 million from the placing, which took place overnight and saw the sale of 28 million shares, versus the original expectation of 22 million shares, at 1,275 pence per share.
----------
FTSE 250 - LOSERS
----------
Enterprise Inns, down 2.0%. Barclays downgraded the pub operator's stock to Underweight from Equalweight.
----------
MAIN MARKET AND AIM - WINNERS
----------
Premier Farnell up 6.8%. The electrical components maker said it has agreed to sell life-safety products business Akron Brass Holding Corp to IDEX Corp for USD224.2 million in cash. The company said it decided to sell Akron Brass, which provides products to fight fire, in order to allow it to invest more in its core electronics distribution arm. The move comes after the completion of an operational review of its global electronics distribution business late last year, with the sale of Akron Brass marking an "important miletone" towards refocusing Premier Farnell and improving its financial performance.

Bahamas Petroleum, up 30%. The oil and gas company said the Bahamian senate approved a Petroleum Bill aimed at improving exploration in the country. The new legislation provides an upgraded and modernised framework for petroleum exploration operations in the Bahamas and are set to guide and govern the next phase of safe and responsible hydrocarbon exploration. The Sovereign Wealth Fund will ensure that wealth generated from exploration success in the country will be invested and conserved to benefit the country's population.

Wishbone Gold, up 10%. The gold miner said it has acquired Precious Metals International, which holds a gold, precious metals and gem trading licence to operate in the United Arab Emirates. Black Sand, which was established by its chief executive Barret Kosh in 2014 as a successor company to Multinational Commodities FZE, has agreements in place for importing gold from Colombia and Honduras with a pipeline of other supply deals from other parts of South America.

----------
MAIN MARKET AND AIM - LOSERS
----------
ImmuPharma, down 14%. The drug development company said it is seeking to raise at least GBP7.5 million through a placing and subscription to finance a trial for its Lupuzor product. ImmuPharma said it will issue no fewer than 11.8 million shares at 26 pence per share, to raise at least GBP3.1 million, in an accelerated bookbuild. In a separate agreement, ImmuPharma set out a subscription deal with Lanstead Capital to raise GBP4.4 million through the subscription of 17.0 million new shares at 10p per share. Of this, the company said it will retain GBP660,000. The remaining GBP3.76 million is to be pledged to Lanstead via a sharing agreement, with ImmuPharma entitled to receive the money over a period of 18 months, with the amount depending on the movement of ImmuPharma's shares.

Central Rand Gold, down 13%. The gold miner said it is raising GBP1.2 million through an equity subscription deal. The company said it plans on issuing just shy of 35.0 million new shares at 3.5 pence per share. It has already allotted 14.3 million new shares, and requires shareholder permission to issue the remainder. The shares have been conditionally subscribed for by a number of high-net-worth individuals including the principal of Zhejiang Golden Machinery Plant. The move comes just weeks after the company terminated talks with four Asian investor groups for the sale of Central Rand Gold (Netherlands Antilles) NV, amid uncertainty over falling commodity prices and a tough time for the junior mining sector.
----------
By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun

Copyright 2016 Alliance News Limited. All Rights Reserved.

More News
2 Apr 2024 12:52

Immupharma jumps amid new IP strategy for P140 technology platform

(Alliance News) - Immupharma PLC on Tuesday announced a new intellectual property strategy to significantly enhance the patent life and commercial value for its P140 technology platform.

Read more
25 Mar 2024 12:20

Incanthera says first order from skincare deal doubles

(Alliance News) - ImmuPharma PLC on Monday noted updates on Incanthera PLC's commercial skincare deal with Marionnaud, which was first announced in December 2023.

Read more
25 Mar 2024 12:09

LONDON MARKET MIDDAY: Stocks make tepid start to new week

(Alliance News) - Stock prices in London were down at midday on Monday, giving back some gains from last week, when equities were boosted by central bank decisions and accompanying statements which investors saw as dovish.

Read more
25 Mar 2024 10:55

AIM WINNERS & LOSERS: ImmuPharma order doubles; Aeorema swings to loss

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Read more
6 Mar 2024 13:05

EARNINGS AND TRADING: Challenger signs farm-out; Ricardo revenue up

(Alliance News) - The following is a round-up of earnings and trading updates of London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
19 Dec 2023 17:52

EARNINGS AND TRADING: Time Finance revenue up; Libertine loss narrows

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
18 Dec 2023 12:18

IN BRIEF: Incanthera signs skincare stocking deal, raises GBP1 million

Incanthera PLC - develops technologies in dermatology and oncology - Raises GBP1.0 million in equity to support a deal that will see a major retailer stock Incanthera's 'Skin + Cell' range of skincare products. Raises GBP800,000 from the subscription to 11.4 million new shares at 7 pence each by new and existing institutional investors. At the same price, the University of Bradford converts GBP200,000 that is owed to it by Incanthera into 2.9 million new shares. The university, a founding shareholder in Incanthera, will own 11.2% of the enlarged share capital, with all the newly issued shares representing 15.5% of this. Incanthera also grants warrants to advisers to subscribe for another 800,000 new shares at the same price of 7p over the next 10 years. ImmuPharma PLC, which currently has a 12.7% stake in Incanthera, says it is "delighted" with the announcement of the skincare deal and successful fundraise.

Read more
7 Sep 2023 17:07

TRADING UPDATES: RA International loss narrows as revenue grows

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
31 Aug 2023 13:05

ImmuPharma launches GBP2 million fund raise as interim loss narrows

(Alliance News) - ImmuPharma PLC on Thursday announced a share placing and a retail share offer to raise just under GBP2 million, while it also reported a narrowed loss in the first half of the year on reduced expenses.

Read more
21 Aug 2023 12:33

ImmuPharma agrees 12 month extension to Incanthera warrant instrument

(Alliance News) - Incanthera PLC and ImmuPharma PLC on Monday agreed a 12 month extension to their warrant instrument.

Read more
23 Jun 2023 15:51

UK shareholder meetings calendar - next 7 days

Monday 26 June 
Aterian PLCAGM
Capricorn Energy PLCAGM
Corre Energy BVAGM
Facilities by ADF PLCAGM
Lexington Gold LtdSGM re proposed acquisition of White Rivers Exploration Ltd
LifeSafe Holdings PLCAGM
Premier African Minerals LtdAGM
Vast Resources PLCGM re issuing new share capital
Volvere PLCAGM
Tuesday 27 June 
Acuity RM Group PLCAGM
Comptoir Group PLCAGM
Creo Medical Group PLCAGM
First Tin PLCAGM
Forward Partners Group PLCAGM
Galantas Gold CorpAGM
Gemfields Group LtdAGM
Golden Prospect Precious Metals LtdAGM
Hamak Gold LtdAGM
ICG Enterprise Trust PLCAGM
Impellam Group PLCAGM
India Capital Growth Fund LtdAGM
Inspiration Healthcare Group PLCAGM
Instem PLCAGM
JD Sports Fashion PLCAGM
Kingfisher PLCAGM
Mercantile Ports & Logistics LtdGM re equity fundraising
Mobile Tornado Group PLCAGM
Revolution Beauty Group PLCAGM
Scottish Mortgage Investment Trust PLCAGM
Serabi Gold PLCAGM
Sondrel Holdings PLCAGM
Surface Transforms PLCAGM
Surgical Innovations Group PLCAGM
Trinity Exploration & Production PLCAGM
Wednesday 28 June 
Atalaya Mining PLCAGM
Avacta Group PLCAGM
Boku IncAGM
Cambridge Cognition Holdings PLCAGM
Cizzle Biotechnology Holdings PLCAGM
Cobra Resources PLCAGM
Cora Gold LtdAGM
Dial Square Investments PLCAGM
Itaconix PLCAGM
NB Distressed Debt Investment Fund LtdAGM
Panthera Resources PLCGM re directors’ authority to allot shares
Phoenix Spree Deutschland LtdAGM
Pineapple Power Corp PLCAGM
Polarean Imaging PLCAGM
RA International Group PLCAGM
Schroder European Real Estate Investment Trust PLCAGM
Shield Therapeutics PLCAGM
St Mark Homes PLCAGM
Star Phoenix Group LtdAGM
ValiRx PLCAGM
Velocys PLCAGM
Vertu Motors PLCAGM
Warpaint London PLCAGM
Westminster Group PLCAGM
Zenova Group PLCAGM
Thursday 29 June 
3i Group PLCAGM
Africa Opportunity Fund LtdAGM
Anemoi International LtdAGM
Anpario PLCAGM
Ariana Resources PLCAGM
Beowulf Mining PLCAGM
Celadon Pharmaceuticals PLCAGM
Cornish Metals IncAGM
East Imperial PLCAGM
East Star Resources PLCAGM
Eden Research PLCAGM
Engage XR Holdings PLCAGM
First Class Metals PLCAGM
Gresham House Energy Storage Fund PLCGM re remuneration policy
Gusbourne PLCAGM
HeiQ PLCAGM
Helios Underwriting PLCAGM
Ingenta PLCAGM
IQE PLCAGM
Kooth PLCAGM
Landore Resources LtdAGM
Let's Explore Group PLCAGM
Likewise Group PLCAGM
MGC Pharmaceuticals LtdGM re issue of convertible notes
Morgan Advanced Materials PLCAGM
NetScientific PLCAGM
New Century AIM VCT 2AGM
Norman Broadbent PLCAGM
Reabold Resources PLCAGM
Rockhopper Exploration PLCAGM
Roquefort Therapeutics PLCAGM
Serica Energy PLCAGM
SpaceandPeople PLCAGM
Symphony Environmental Technologies PLCAGM
Synairgen PLCAGM
Thalassa Holdings LtdAGM
tinyBuild IncAGM
Touchstone Exploration IncAGM
Trident Royalties PLCAGM
Unigel Group PLCAGM
Verici Dx PLCAGM
Xpediator PLCAGM
Friday 30 June 
Argo Blockchain PLCAGM
Ascent Resources PLCAGM
Bluejay Mining PLCAGM
Caspian Sunrise PLCAGM
Codex Acquisitions PLCAGM
Domino's Pizza Group PLCGM re directors' remuneration policy
Fenikso LtdAGM
Fiinu PLCAGM
FireAngel Safety Technology Group PLCAGM
GENinCode PLCAGM
Hemogenyx Pharmaceuticals PLCAGM
Hiro Metaverse Acquisitions I SAAGM
i3 Energy PLCGM re premium share cancellation
ImmuPharma PLCAGM
Inspired PLCAGM
Jadestone Energy PLCAGM
Kanabo Group PLCAGM
Kefi Gold & Copper PLCAGM
Kistos Holdings PLCAGM
KRM22 PLCAGM
Kropz PLCAGM
LoopUp Group PLCAGM
Medica Group PLCAGM
Mirriad Advertising PLCAGM
Rockfire Resources PLCAGM
Savannah Energy PLCAGM
Strip Tinning Holdings PLCAGM
ThomasLloyd Energy Impact Trust PLCAGM
URA Holdings PLCAGM
World Chess PLCAGM
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
19 Jun 2023 12:02

IN BRIEF: ImmuPharma to start next two phases of Lupuzor trial

ImmuPharma PLC - London-based drug discovery and development company - Will start phases two and three of the clinical trial for Lupuzor in the seocnd half of 2023, following talks with the US Food & Drug Administration. Says the clinical trial will be supported by Avion Pharmaceuticals. Adds further details of the trial will be shared at a later stage. Lupuzor, or P140, is a potential treatment for Lupus disease.

Read more
18 May 2023 12:12

IN BRIEF: ImmuPharma rises on FDA feedback for neurological disease

ImmuPharma PLC - London-based drug discovery and development company - Gets positive support and guidance from the US Food & Drug Administration after a pre-investigational new drug meeting, which confirms the route for a Phase 2/3 adaptive clinical study of P140 in chronic idiopathic demyelinating polyneuropathy. Says the feedback recognises that P140 is suitable to be studied in another disease indication, in addition to systemic lupus erythematosus.

Read more
11 May 2023 11:48

IN BRIEF: ImmuPharma annual loss narrows as R&D spending reduced

ImmuPharma PLC - London-based drug discovery and development company - Posts no revenue for 2022, compared to GBP118,350 for 2021. Pretax loss narrows to GBP4.5 million from GBP8.9 million a year earlier, as operating loss reduces to GBP3.0 million from GBP6.6 million. Research and development expenditure is GBP2.0 million, down from GBP3.7 million in 2021. Chief Executive Officer Tim McCarthy says: "As a board, we remain focused on bringing our two key late stage clinical assets, Lupuzor for lupus and CIDP closer to the market."

Read more
19 Apr 2023 15:40

IN BRIEF: ImmuPharma says US FDA confirms date for Lupuzor meeting

ImmuPharma PLC - London-based drug discovery and development company - Notes the US Food & Drug Administration has set a date of June 7 for a type-C meeting to provide guidance on the phase 2/3 adaptive study of Lupuzor, or P140, in patients with systemic lupus erythematosus, a common type of immune disease lupus. Says this follows the announcement in late March, when it submitted a phase 2/3 clinical trial protocol to the US FDA testing the Lupuzor treatment for lupus patients.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.